Markets have been risk-on, risk-off for most of June and July this year. Ditto interest rates and trade issues. Tuesday's action proves the point, focused as it is on Federal Reserve policy.
AbbVie (trading symbol: ABBV) announced it would acquire fellow drug giant, the perpetually ailing Allergan (AGN), in a massive cash and stock deal.
The reported Iran oil tanker attack goosed the per barrel price of crude oil Thursday and Friday. Meanwhile, Broadcom shares entered smackdown territory.
Our old reliable McClellan Oscillator popped above the zero line for the first time since… whenever. But averages refuse to break above their April highs.
No improvement in the China trade talks as big New York banks and investment houses trumpet recession fears. It's post-Memorial Day Blues time for stocks.
The S&P 500 and the tech-heavy NASDAQ, down earlier, have broken back into the green zone. The reason: Today's FOMC report was clearly dovish.
China trade talks optimism, crude oil price jump dominate Monday trading action on Wall Street as major market averages jump again.
Washington rumors, hearsay and crystal ball readings began to predict that Congress had coalesced around a compromise Federal budget breakthrough bill.
Allergan (AGN) and Clearway Energy A (CWEN/A) shares are stinking up our portfolio. Should we continue to hold, or should we sell?
Some traders and investors bet on the Super Bowl Indicator every year. While it isn’t a perfect market indicator, it’s worked somewhat more often than not.
As we’ve seen over the last several months, Thursday's mellow market mood may have nothing to do with how stocks close at 4 p.m.
You will be a pessimist if you look too closely at plummeting oil prices, and / or efforts by America's Corruptocrats to nullify key Republican gains by “finding” heretofore hidden crates of tombstone voters and votes.
This current leg of the Great Trump Rally is beginning to look a little weird. Tired. Weary. Maybe even a bit green behind the gills.
Blasting to the upside were a pair of pharmaceutical stocks, one old — Allergan (trading symbol: AGN) — and one brand new — Elanco (ELAN), an IPO that debuted Thursday morning.
As if to echo the current Trump-China tariff malaise, weather on America's east coast provided a melancholy backdrop the doleful mood on Wall Street.
Even our favorite ETFs (discussed in the concluding article of yesterday’s ETF trilogy) were looking anemic as we limped toward Friday’s close. Maybe they've become another casualty of Wall Street's chronically overbought markets.
As we conclude this piece, the NASDAQ is once again attempting to rise from the dead. But we'll believe in tech again when it can continue to rise for several trading days in a row. So far we're still waiting.
Logically, we now turn to the crucial matter of making stock portfolio repairs. If we're successful, we should be able to profitably ride out the slings and arrows of a volatile Q2 2018.
Let’s just spend a few paragraphs on today’s current and rather remarkable Wall Street rally. Then, we will exit before Wacky Wednesday deposits egg on our analytical faces.
Rally 2018 resumed with a vengeance, and Wall Street records were shattered again as both the tech-heavy NASDAQ and the broad-based S&P 500 averages hit new record highs.